Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) ...

Collaboration Revenue: Collaboration revenue was $1.5 million for the three months ended June 30, 2025, as compared to no collaboration revenue for the three months ended June 30, 2024. The increase ...

Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines Agen ...

Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma ...

NRX.V READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) (TSX:NRX.V) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also ...

Importantly, these exosomes were produced from NurExone’s proprietary master cell bank, whose cells are maintained under ...

Developed by regenerative nanomedicine pioneer Samuel I. Stupp, the therapy harnesses molecular motion to reverse paralysis and repair tissues after traumatic spinal cord injuries.

DelveInsight’s, “ Idiopathic Pulmonary Fibrosis Pipeline Insights 2025 ” report provides comprehensive insights about 80+ ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that the ...

Q2 2025 Earnings Call Transcript August 1, 2025 Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.05, ...

The legal battle over the scope of orphan drug exclusivity continues, as the U.S. Food and Drug Administration (“FDA”) has recently lost a second ...

The FDA awarded orphan drug designation to VT3989 for mesothelioma, supporting the experimental cancer treatment’s ...